Effect of venovenous extracorporeal membrane oxygenation on the heart in a healthy piglet model
© Shen et al.; licensee BioMed Central Ltd. 2013
Received: 4 March 2013
Accepted: 7 June 2013
Published: 28 June 2013
Cardiac function is important for patients treated by venovenous extracorporeal membrane oxygenation (VV ECMO), but data about the effect of VV ECMO on the heart in nonneonates is absent. We studied the effect of VV ECMO on cardiac performance, cardiomyocyte and mitochondria in an animal model.
Twelve farm piglets were randomly assigned into two groups: control group and ECMO group. In the ECMO group, ECMO cannulaes were placed and ECMO was instituted. Hemodynamics was recorded at baseline, 1 hour after induction, and every 4 hours thereafter, to assess the cardiac performance. All animals were monitored for 24 hours and were euthanized and myocardium was harvested. Myocardial histology, ultrastructure of cardiomyocyte and mitochondria were observed, and activities of mitochondrial complexes I-V were measured, to assess the effect to cardiomyocyte and mitochondria.
Hemodynamics were stable in each group of animals throughout the experiment. Interstitial edema, disorderd and dissolved of focal myofilament, morphological deformations of mitochondria were observed in the ECMO group. The activities of mitochondrial complexes were decreased in the ECMO group, and complex I and IV reached significance.
VV ECMO therapy is associated with changes of ultrastructure and function of cardiomyocyte and mitochondria, inducing myocardium injury. However, the injury was mild and had no effect on the cardiac performance for healthy piglets.
Venovenous extracorporeal membrane oxygenation (VV ECMO) is a life-saving treatment for severe respiratory failure patient refractory to conventional therapy. VV ECMO maintains sufficient tissue oxygenation and carbon dioxide elimination, so that ventilator settings can be reduced which minimizes ventilator-induced lung injury, and provides time for lung to rest and recovery [1, 2]. The improved survival of patients randomized to the ECMO arm in the CESAR research  and the successful use of ECMO in the 2009 H1N1 pandemic  brought ECMO into the spotlight of the world, and VV ECMO is coming into wider use . However, the overall survival of VV ECMO for severe respiratory failure patients was about 50%-60% [6–8], remains for further improvement.
VV ECMO does not provide direct cardiac support, which depends on intrinsic cardiac function to maintain cardiac output. In the clinical practice, we found that there are some patients developing cardiac dysfunction during VV ECMO therapy, and finally lead to adverse outcome. Therefore, we postulate that myocardial dysfunction plays an important role in determining the outcome of patients treated by VV ECMO, and the possibility of VV ECMO inducing cardiac injury is important.
Very little is known about the effect of VV ECMO on the heart, limited to some clinical observations in neonates [9, 10], and absent in pediatric and adult populations. Strleper et al.  evaluated the effect of VV ECMO on cardiac performance by echocardiography in 15 infants, and found no deleterious effect. Roberts et al.  reported that VV ECMO is safe for inotrope dependent neonates. But it remains unclear whether VV ECMO has some potentially adverse effect on the heart, especially for nonneonatal population.
The aim of the study was to investigate the effect of VV ECMO on the heart in nonneonatal population. Patients with severe respiratory failure have a high prevalence of cardiac dysfunction [11, 12]. To avoid the confounding effect of the disease condition, we performed this study in a healthy piglet model. Hemodynamics were monitored to evaluate cardiac performance. As the fundamental of cardiac function, cardiomyocyte and mitochondria were studied to find slighter and earlier stage of changes.
This study was approved by the Animal Care Committee of Jinling Hospital. All animals received humane care in accordance with the “Principles of Laboratory Animal Care” formulated by the Ministry of Health of the People’s Republic of China.
Twelve farm piglets of either sex (25–35 kg) were fasted for 24 hrs. Anesthesia was induced with ketamine (20 mg/kg), diazepam (8 mg/kg), and atropine (0.1 mg/kg) intramuscularly, maintained with ketamine (10-20 mg/kg/hr) and diazepam (8 mg/kg/hr) intravenously. The animals were intubated through a cervical tracheotomy, and ventilated on volume-control mode with room air at a tidal volume setting of 5–8 mL/kg, positive end expiratory pressure of 5 mmHg, and respiratory rate of 15 breaths per minute. Internal jugular vein and femoral arterial catheters were aseptically placed for intravenous access, blood pressure monitoring, and sample collection, pulmonary artery catheter was inserted in the proximal pulmonary artery via the jugular vein catheter for monitoring of pulmonary artery pressure (PAP) and pulmonary artery occlusion pressure (PAOP).
After instrumentation and baseline data collection, animals were randomly assigned into two groups: control group and ECMO group (n =6/each). In the ECMO group, after a 150 U/kg intravenous bolus of heparin, ECMO cannulaes (15 F, Medtronic, Minneapolis, Minnesota) were placed in the superior vena cava through internal jugular vein and inferior vena cava through femoral vein, and ECMO circulation was instituted. Placement of the cannulaes was confirmed via ultrasonograph. Heparin was infused to keep activated clotting time of 180–220 seconds after insertion.
The ECMO system consisted of a membrane oxygenator and tubing (Quadrox PLS, Maquet, Rastatt, Germany), a centrifugal pump (Rotaflow Console, Maquet, Rastatt, Germany), a heat exchange (Heater-Cooler Unit HCU 30, Maquet, Rastatt, Germany). The circuit was primed with 500 ml hydroxyethyl starch 130/0.4 and 200-300 ml Ringer’s lactate. Blood in circuit was drained from femoral vein cannulae and infused into internal jugular vein cannulae at a flow rate of 50 ml/(kg.min). 100% oxygen was given at a flow rate equal to the blood flow rate.
Hemodynamic parameters, including heart rate (HR), mean arterial pressure (MAP), mean pulmonary artery pressure (MPAP) and pulmonary artery occlusion pressure (PAOP) were monitored (PiCCO2, PULSION, Munich, Germany) and recorded at baseline, 1 hour after induction, and every 4 hours thereafter until 24 hours. All pressures were determined at end-expiration. Each animal received lactated Ringer’s solution at a rate of 3 ml/kg/h, and bolus fluid was provided as required to maintain MAP above 60 mmHg. The whole volume of fluid intake of each animal was recorded. Temperature, Serum pH, glucose and ionized calcium concentration were monitored and maintained normally.
All animals were monitored for 24 hours and were euthanized with a bolus injection of potassium chloride (40 ml, 0.1 g/ml). Myocardium was harvested immediately for further measuring.
Myocardial histology examination
Samples from the apex of left ventricular muscle were fixed and dehydrated with 10% formalin, embedded in paraffin, cutted into sections, stained with hematoxylin and eosin (H and E staining), and observed by an optical microscopy (CX41, Olympus, Tokyo, Japan).
Myocardial ultrastructure examination
Fresh myocardial tissues from the apex of left ventricular muscle were cut into pieces (1*1*1 mm), fixed with 3% glutaraldehyde, flushed with phosphate-buffered saline, fixed with 1% perosmic acid, and dehydrated with acetone. Ultrathin sections were placed on 200-mesh copper grids and double stained with 4% uranyl acetate and 0.2% lead citrate. Sections were examined under transmission electron microscopy (TEM, JEM-1010, JEOL, Tokyo, Japan). Ultrastructure of cardiomyocyte and mitochondria was observed.
The histology and ultrastructure were examined by an independent pathologist blinded to the grouping.
Mitochondrial isolation and measurement of mitochondrial complexes activities
Heart tissues from the apex of left ventricular muscle were put in the ice-cold homogenization buffer. The mitochondrial pellet was isolated by differential centrifugation , and finally resuspended in phosphate buffer. Mitochondrial protein concentration was determined using the method of Bradford .
Activities of mitochondrial respiratory chain complexes I-V were measured using spectrophotometry . The activity of complex I was expressed as μmoles of nicotinamide adenine dinucleotide reduced (NADH) oxidized/min/mg protein, the activity of complex II was expressed as μmoles of 2,6-diclorophenol indophenol (DCIP) oxidized/min/mg protein, the activity of complex III was expressed as μmoles of decylubiquinol oxidized/min/mg protein, the activity of complex IV was expressed as μmoles of cytochrome c oxidized/min/mg protein, the activity of complex V was expressed as μmoles of NADH oxidized/min/mg protein.
All the statistical analyses of the data were performed by the SPSS 17.0 software (SPSS Inc., Chicago, Illinois). Data are expressed as mean ± SD or median (interquartile range). Data were statistically analyzed using one-way analysis of variance (ANOVA). Significant results were post hoc analyzed, using the least significance difference (LSD) tests. Statistical significance was established as p <0 .05.
There was no difference in body weight and other characteristic between groups.
Hemodynamics and fluid intake
Time course of hemodynamics in the two groups
136 ± 10.1
130 ± 13.7
126 ± 10.3
123 ± 11.8
124 ± 14.5
128 ± 14.5
131 ± 10.4
134 ± 4.9
140 ± 12.4
130 ± 12.5
133 ± 10.4
128 ± 10.9
124 ± 15.2
128 ± 10.4
70 ± 6.5
72 ± 8.5
76 ± 9.3
75 ± 8.5
70 ± 9.1
75 ± 9.9
75 ± 9.3
67 ± 5.0
68 ± 9.5
73 ± 9.4
71 ± 9.1
77 ± 10.6
76 ± 8.5
73 ± 9.9
17.7 ± 4.0
19.2 ± 4.0
18.2 ± 3.3
19.0 ± 3.6
18.8 ± 3.9
16.7 ± 4.0
18.3 ± 4.0
18.5 ± 3.1
20.2 ± 4.4
19.5 ± 4.5
20.2 ± 4.6
19.3 ± 4.0
19.0 ± 3.1
18.7 ± 3.6
12.0 ± 2.1
11.7 ± 1.2
11.3 ± 1.9
11.0 ± 0.9
11.2 ± 1.2
11.7 ± 1.9
11.5 ± 1.2
11.2 ± 1.5
11.0 ± 1.1
11.8 ± 1.2
12.0 ± 0.9
12.0 ± 1.7
11.8 ± 1.6
12.0 ± 1.4
Myocardial histology and ultrastructure changes
Mitochondrial structure and function
As a lifesaving treatment, VV ECMO is becoming more and more essential for children and adults with refractory respiratory failure, and such patients have a high prevalence of cardiac dysfunction [11, 12]. VV ECMO does not provide direct cardiac support, which depends on intrinsic cardiac function to maintain cardiac output. Therefore, the condition of cardiac function during VV ECMO is closely associated with the outcome. We present the first detailed laboratory investigation in the effect of VV ECMO on the heart in nonneonatal population.
In this study, the volume of fluid intake was significantly more in the ECMO group. Golej et al.  found MAP decreased at the initiation of VV ECMO and increased in a short time. In consideration of the numerous influence factors, we haven`t analyzed the immediate hemodynamic response. But we have observed similar MAP fluctuation at the initiation of VV ECMO and restored quickly after fluid bolus, which contributed a lot to the amount of the fluid taken in the ECMO group, and may associated with myocardium interstitial edema.
In addition, the ECMO group disorderd and dissolved of focal myofilament, morphological deformations of mitochondria and decreased activities of mitochondrial complexes compared with the control group, suggesting that VV ECMO therapy is associated with myocardium injury.
The mechanisms of these findings require further research. Several factors may contribute to it, such as activation of systemic inflammatory response, increase of reactice oxygen species (ROS), and release of toxic substances by ECMO.
The instigation of a systemic inflammatory state with exposure to ECMO is well accepted [17–21]. Fortenberry et al.  found that neutrophil was activated and concentration of circulating interleukin (IL)-8 increased significantly after ECMO initiation. Adrian et al.  perfused blood in vitro ECMO circuit performed for 24 hours, and found cytokines, including IL-1β, IL-1 receptor antagonist, IL-8, IL-6, tumor necrosis factor α (TNF-α) were increased. Mu et al.  found concentrations of circulating IL-6 and IL-10 increased significantly in a hemorrhage-reperfusion piglet model on modern ECMO. The inflammatory cytokines have been implicated in mediating myocardial injury [22–24]. Deng et al.  and Hennein et al.  found that preoperative left ventricular dysfunction is associated with the degree of proinflammatory cytokine release. Liakopoulos et al.  found that cardiac dysfunction occurred after cardiopulmonary bypass was associated with the increase of systemic and myocardial TNF-α, and anti-inflammatory pretreatment with methylprednisolone abolished the increase of TNF-α attenuated myocardial dysfunction.
It is well established that cardiopulmonary bypass is associated with increased production of reactice oxygen species (ROS) [28, 29], and similar results were verified during ECMO therapy. Hirthler et al.  and Underwood et al.  detected that systemic free radical was increased during ECMO. Moller et al.  found free oxygen radical scavenging enzymes such as superoxide dismutase and glutathione reductase were decreased during ECMO in healthy lambs, resulted in increased lipoperoxide level. ROS are central mediators of cardiac injury, especially for mitochondria, and finally resulting in cardiac dysfunction . Precious researches indicate that lacking of ROS scavenging enzyme aggravate myocardial injury , and antioxidant potentiate cardiac protection .
Despite changes of ultrastructure and function of cardiomyocyte and mitochondria induced by VV ECMO, we found hemodynamics during VV ECMO therapy was stable, suggesting that the injury was mild, and had no effect on the cardiac performance for healthy piglets, consistently with the results of Strieper  and Roberts .
However, energy is the base to maintain normal cardiac pump function, continuously produced by mitochondrial respiration . Therefore, any alteration of mitochondrial structure and function are fundamental for cardiac function. The changes of mitochondria in this study do not impact the cardiac performance, but may impact the cardiac reserved function, which may essential for a marginally functional heart or when cardiac demand increased under disease conditions.
Furthermore, under disease conditions with severe hypoxia, hypoxia itself plays an important role in myocardial injury , and the advantage of VV ECMO in providing adequate oxygenation to the myocardium may be of protective effect. Shen et al.  found cardiac dysfunction due to hypoxia coronary perfusion during venoarterial ECMO in a hypoxemic swine model, postulating that VV ECMO may be more adequate for hypoxemic condition. However, abrupt hyperoxia for a hypoxemic heart may induce reoxygenation injury, causing further cardiac injury. Allen et al.  and Trittenwein et al.  found increased amounts of oxygen free radicals after reoxygenation on cardiopulmonary bypass and ECMO respectively.
Therefore, the effect of VV ECMO on the myocardium and cardiac performance would be more complicated for patients under hypoxemic condition, and should be further investigated. However, we present the potentially adverse effect of VV ECMO alone on the heart for the first time, calling for attention to the impact on heart during VV ECMO, and provide a potentially aspect to improve the survival of VV ECMO.
In conclusion, the results of our study showed that VV ECMO is associated with changes of ultrastructure and function of cardiomyocyte and mitochondria, inducing myocardium injury. The underlying mechanisms should be further investigated. However, the injury was mild and had no effect on the cardiac performance for healthy piglets.
Extracorporeal membrane oxygenation
Mean arterial pressure
Mean pulmonary artery pressure
Pulmonary artery occlusion pressure
- H and E staining:
Stained with hematoxylin and eosin
Transmission electron microscopy
Nicotinamide adenine dinucleotide reduced
Reactice oxygen species
Tumor necrosis factor α.
This study was supported by 12th five-year Major Program of Army Grants (NO. AWS11J03; NO. AWS12J001); Jiangsu Province's Special Project of Science and Techonology in Medicine (BL2012006); Jiangsu Province's Key Medical Talent Program (RC2011128).
- Maclaren G, Combes A, Bartlett RH: Contemporary extracorporeal membrane oxygenation for adult respiratory failure: life support in the new era. Intensive Care Med. 2012, 38: 210-220. 10.1007/s00134-011-2439-2.View ArticlePubMedGoogle Scholar
- Tiruvoipati R, Botha J, Peek G: Effectiveness of extracorporeal membrane oxygenation when conventional ventilation fails: valuable option or vague remedy?. J Crit Care. 2012, 27: 192-198. 10.1016/j.jcrc.2011.04.003.View ArticlePubMedGoogle Scholar
- Peek GJ, Mugford M, Tiruvoipati R: Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009, 374: 1351-1363. 10.1016/S0140-6736(09)61069-2.View ArticlePubMedGoogle Scholar
- Noah MA, Peek GJ, Finney SJ: Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA. 2011, 306: 1659-1668. 10.1001/jama.2011.1471.View ArticlePubMedGoogle Scholar
- Dalton HJ: Extracorporeal life support: moving at the speed of light. Respir Care. 2011, 56: 1445-1453. 10.4187/respcare.01369.View ArticlePubMedGoogle Scholar
- Brogan TV, Thiagarajan RR, Rycus PT, Bartlett RH, Bratton SL: Extracorporeal membrane oxygenation in adults with severe respiratory failure: a multi-center database. Intensive Care Med. 2009, 35: 2105-2114. 10.1007/s00134-009-1661-7.View ArticlePubMedGoogle Scholar
- Zabrocki LA, Brogan TV, Statler KD, Poss WB, Rollins MD, Bratton SL: Extracorporeal membrane oxygenation for pediatric respiratory failure: Survival and predictors of mortality. Crit Care Med. 2011, 39: 364-370. 10.1097/CCM.0b013e3181fb7b35.View ArticlePubMedGoogle Scholar
- Schmid C, Philipp A, Hilker M: Venovenous extracorporeal membrane oxygenation for acute lung failure in adults. J Heart Lung Transplant. 2012, 31: 9-15. 10.1016/j.healun.2011.07.013.View ArticlePubMedGoogle Scholar
- Strieper MJ, Sharma S, Dooley KJ, Cornish JD, Clark RH: Effects of venovenous extracorporeal membrane oxygenation on cardiac performance as determined by echocardiographic measurements. J Pediatr. 1993, 122: 950-955. 10.1016/S0022-3476(09)90026-9.View ArticlePubMedGoogle Scholar
- Roberts N, Westrope C, Pooboni SK: Venovenous extracorporeal membrane oxygenation for respiratory failure in inotrope dependent neonates. ASAIO J. 2003, 49: 568-571. 10.1097/01.MAT.0000084102.22059.91.View ArticlePubMedGoogle Scholar
- Zimmerman GA, Morris AH, Cengiz M: Cardiovascular alterations in the adult respiratory distress syndrome. Am J Med. 1982, 73: 25-34. 10.1016/0002-9343(82)90920-2.View ArticlePubMedGoogle Scholar
- Bajwa EK, Boyce PD, Januzzi JL, Gong MN, Thompson BT, Christiani DC: Biomarker evidence of myocardial cell injury is associated with mortality in acute respiratory distress syndrome. Crit Care Med. 2007, 35: 2484-2490. 10.1097/01.CCM.0000281852.36573.22.View ArticlePubMedGoogle Scholar
- Poderoso JJ, Carreras MC, Lisdero C, Riobo N, Schopfer F, Boveris A: Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. Arch Biochem Biophys. 1996, 328: 85-92. 10.1006/abbi.1996.0146.View ArticlePubMedGoogle Scholar
- Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3.View ArticlePubMedGoogle Scholar
- Sudheesh NP, Ajith TA, Janardhanan KK: Ganoderma lucidum (Fr.) P. Karst enhances activities of heart mitochondrial enzymes and respiratory chain complexes in the aged rat. Biogerontology. 2009, 10: 627-636. 10.1007/s10522-008-9208-9.View ArticlePubMedGoogle Scholar
- Golej J, Kahlbacher H, Schoffmann G: The immediate haemodynamic response to the initiation of extracorporeal membrane oxygenation in a piglet model of infant hypoxic respiratory failure. Perfusion. 2002, 17: 421-426. 10.1191/0267659102pf609oa.View ArticlePubMedGoogle Scholar
- Hirthler M, Simoni J, Dickson M: Elevated levels of endotoxin, oxygen-derived free radicals, and cytokines during extracorporeal membrane oxygenation. J Pediatr Surg. 1992, 27: 1199-1202. 10.1016/0022-3468(92)90787-8.View ArticlePubMedGoogle Scholar
- Underwood MJ, Pearson JA, Waggoner J, Lunec J, Firmin RK, Elliot MJ: Changes in "inflammatory" mediators and total body water during extra-corporeal membrane oxygenation (ECMO). A preliminary study. Int J Artif Organs. 1995, 18: 627-632.PubMedGoogle Scholar
- Fortenberry JD, Bhardwaj V, Niemer P, Cornish JD, Wright JA, Bland L: Neutrophil and cytokine activation with neonatal extracorporeal membrane oxygenation. J Pediatr. 1996, 128: 670-678. 10.1016/S0022-3476(96)80133-8.View ArticlePubMedGoogle Scholar
- Adrian K, Mellgren K, Skogby M, Friberg LG, Mellgren G, Wadenvik H: Cytokine release during long-term extracorporeal circulation in an experimental model. Artif Organs. 1998, 22: 859-863. 10.1046/j.1525-1594.1998.06121.x.View ArticlePubMedGoogle Scholar
- Mu TS, Palmer EG, Batts SG, Lentz-Kapua SL, Uyehara-Lock JH, Uyehara CF: Continuous renal replacement therapy to reduce inflammation in a piglet hemorrhage-reperfusion extracorporeal membrane oxygenation model. Pediatr Res. 2012, 72: 249-255. 10.1038/pr.2012.69.View ArticlePubMedGoogle Scholar
- Mann DL: The effect of tumor necrosis factor-alpha on cardiac structure and function: a tale of two cytokines. J Card Fail. 1996, 2: S165-S172.View ArticlePubMedGoogle Scholar
- Ungureanu-Longrois D, Balligand JL, Kelly RA, Smith TW: Myocardial contractile dysfunction in the systemic inflammatory response syndrome: role of a cytokine-inducible nitric oxide synthase in cardiac myocytes. J Mol Cell Cardiol. 1995, 27: 155-167. 10.1016/S0022-2828(08)80015-6.View ArticlePubMedGoogle Scholar
- Zhang M, Chen L: Status of cytokines in ischemia reperfusion induced heart injury. Cardiovasc Hematol Disord Drug Targets. 2008, 8: 161-172. 10.2174/187152908785849116.View ArticlePubMedGoogle Scholar
- Deng MC, Dasch B, Erren M, Mollhoff T, Scheld HH: Impact of left ventricular dysfunction on cytokines, hemodynamics, and outcome in bypass grafting. Ann Thorac Surg. 1996, 62: 184-190. 10.1016/0003-4975(96)00230-5.View ArticlePubMedGoogle Scholar
- Hennein HA, Ebba H, Rodriguez JL: Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg. 1994, 108: 626-635.PubMedGoogle Scholar
- Liakopoulos OJ, Teucher N, Muhlfeld C: Prevention of TNFalpha-associated myocardial dysfunction resulting from cardiopulmonary bypass and cardioplegic arrest by glucocorticoid treatment. Eur J Cardiothorac Surg. 2006, 30: 263-270. 10.1016/j.ejcts.2006.04.019.View ArticlePubMedGoogle Scholar
- Cavarocchi NC, England MD, Schaff HV: Oxygen free radical generation during cardiopulmonary bypass: correlation with complement activation. Circulation. 1986, 74: III130-III133.PubMedGoogle Scholar
- Clermont G, Vergely C, Jazayeri S: Systemic free radical activation is a major event involved in myocardial oxidative stress related to cardiopulmonary bypass. Anesthesiology. 2002, 96: 80-87. 10.1097/00000542-200201000-00019.View ArticlePubMedGoogle Scholar
- Moller J, Gilman JT, Sussmane J, Raszynski A, Wolfsdorf J: Changes in plasma levels of oxygen radical scavenging enzymes during extracorporeal membrane oxygenation in a lamb model. Biol Neonate. 1993, 64: 134-139. 10.1159/000243983.View ArticlePubMedGoogle Scholar
- Kevin LG, Novalija E, Stowe DF: Reactive oxygen species as mediators of cardiac injury and protection: the relevance to anesthesia practice. Anesth Analg. 2005, 101: 1275-1287. 10.1213/01.ANE.0000180999.81013.D0.View ArticlePubMedGoogle Scholar
- Jain M, Cui L, Brenner DA: Increased myocardial dysfunction after ischemia-reperfusion in mice lacking glucose-6-phosphate dehydrogenase. Circulation. 2004, 109: 898-903. 10.1161/01.CIR.0000112605.43318.CA.View ArticlePubMedGoogle Scholar
- Tsai MS, Huang CH, Tsai CY: Ascorbic acid mitigates the myocardial injury after cardiac arrest and electrical shock. Intensive Care Med. 2011, 37: 2033-2040. 10.1007/s00134-011-2362-6.View ArticlePubMedGoogle Scholar
- Karle VA, Short BL, Martin GR: Extracorporeal membrane oxygenation exposes infants to the plasticizer, di(2-ethylhexyl)phthalate. Crit Care Med. 1997, 25: 696-703. 10.1097/00003246-199704000-00023.View ArticlePubMedGoogle Scholar
- Ventura-Clapier R, Garnier A, Veksler V: Energy metabolism in heart failure. J Physiol. 2004, 555: 1-13.View ArticlePubMedGoogle Scholar
- Shen I, Levy FH, Benak AM: Left ventricular dysfunction during extracorporeal membrane oxygenation in a hypoxemic swine model. Ann Thorac Surg. 2001, 71: 868-871. 10.1016/S0003-4975(00)02281-5.View ArticlePubMedGoogle Scholar
- Allen BS, Rahman S, Ilbawi MN: Detrimental effects of cardiopulmonary bypass in cyanotic infants: preventing the reoxygenation injury. Ann Thorac Surg. 1997, 64: 1381-1388. 10.1016/S0003-4975(97)00905-3.View ArticlePubMedGoogle Scholar
- Trittenwein G, Rotta AT, Gunnarsson B, Steinhorn DM: Lipid peroxidation during initiation of extracorporeal membrane oxygenation after hypoxia in endotoxemic rabbits. Perfusion. 1999, 14: 49-57. 10.1177/026765919901400108.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.